sellWeak
Venrock Healthcare Capital Partners III, L.P. sold $3.7M of KALV
owner at KalVista Pharmaceuticals, Inc.. 214,631 shares at an average of $17.20, traded Mar 25, 2026, filed Mar 27, 2026.
Warning score
37Value
$3.7M
214,631 shares
Holdings after
5,089,354
-4% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +12Role10% owner
- +25Trade size$3.7M at market
- 0Share of holdings soldSold 4.0% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001231919-26-000286, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 25, 2026 | SOpen-market sale Common Stockindirect: By Funds | -174,485 | $16.95 | $3.0M | 5,129,500 | Mar 27, 2026 |
| Mar 25, 2026 | SOpen-market sale Common Stockindirect: By Funds | -160 | $17.53 | $2,805 | 5,129,340 | Mar 27, 2026 |
| Mar 26, 2026 | SOpen-market sale Common Stockindirect: By Funds | -21,386 | $17.76 | $380k | 5,107,954 | Mar 27, 2026 |
| Mar 26, 2026 | SOpen-market sale Common Stockindirect: By Funds | -15,417 | $18.82 | $290k | 5,092,537 | Mar 27, 2026 |
| Mar 26, 2026 | SOpen-market sale Common Stockindirect: By Funds | -3,183 | $19.12 | $61k | 5,089,354 | Mar 27, 2026 |
Related signals
Other insiders at KalVista Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 44Moderate | KalVista Pharmaceuticals, Inc. | Christopher Yea CHIEF DEVELOPMENT OFFICER | $905k 33,800 shares | -13% | |
| 22Weak | KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $60k 2,239 shares | -1% | |
| 22Weak | KalVista Pharmaceuticals, Inc. | Christopher Yea CHIEF DEVELOPMENT OFFICER | $53k 1,966 shares | -1% | |
| 21Weak | KalVista Pharmaceuticals, Inc. | Nicole Sweeny Chief Commercial Officer | $40k 1,489 shares | -2% | |
| 23Weak | KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $72k 2,685 shares | -2% | |
| 39Weak | KalVista Pharmaceuticals, Inc. | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | $293k 10,926 shares | -2% | |
| 23Weak | KalVista Pharmaceuticals, Inc. | Christopher Yea CHIEF DEVELOPMENT OFFICER | $63k 2,358 shares | -1% | |
| 28Weak | KalVista Pharmaceuticals, Inc. | Brian Piekos Chief Financial Officer | $40k 1,489 shares | -6% | |
| 22Weak | KalVista Pharmaceuticals, Inc. | Nicole Sweeny Chief Commercial Officer | $50k 1,861 shares | -3% | |
| 20Weak | KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $28k 1,032 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.